76794-58-6

Upstream product

• 81426-65-5 (R)-(+)-2-Methylbutane-1,2,4-triol 
• 81426-68-8 (R)-dimethyl 2-hydroxy-2-methylsuccinate 
• 131700-28-2 (S)-2,2,4-trimethyl-4-<2-(phenylmethoxy)ethyl>-1,3-dioxolane 
• 131700-29-3 (S)-2-methyl-4-(2-phenylmethoxy)butane-1,2-diol 
• 58558-53-5 (((3-methylbut-3-en-1-yl)oxy)methyl)benzene 
• 763-32-6 2-methyl-1-buten-4-ol 
• 60299-29-8 (S)-(-)-2-Methylbutane-1,2,4-triol 
• 6236-09-5 (S)-citramalic acid 
• 64018-43-5 2-[(4S)-2,2,4-trimethyl-1,3-dioxolan-4-yl]ethanol 
• 98-59-9 p-toluenesulfonyl chloride 

Downstream Products

• 1303609-31-5 (S)-N-benzyl-2-(2,2,4-trimethyl-1,3-dioxolan-4-yl)ethanamine 
• 80321-18-2 (R)-1,2-isopropylidene-2-methyl-4-phenylsulphonylbutane-1,2-diol 
• 80320-82-7 C₅₀H₇₁N₃O₈SSi 
• 80320-84-9 C₄₄H₆₅N₃O₅Si 
• 80321-17-1 (S)-2,2,4-Trimethyl-4-(2-phenylsulfanyl-ethyl)-[1,3]dioxolane 

Relevant academic research and scientific papers

SPIRO-OXINDOLE MDM2 ANTAGONISTS

Provided herein are compounds, compositions, and methods in the field of medicinal chemistry. The compounds and compositions provided herein relate to spiro-oxindoles which function as antagonists of the interaction between p53 and MDM2, and their use as

The first synthesis of geranyllinalool enantiomers

(3R)-(-)-Geranyllinalool and its (3S)-(+)-isomer were synthesized in 7 steps starting from both enantiomers of citramalic acid and geranyl bromide. The synthetic sequence established the absolute configurations of naturally occurring geranyllinalools for